Despite Promise To Be Pro-Life ‘Ally,’ Trump Admin Won’t Regulate Abortion Drug Endangering Women
It is well established that mifepristone, the popular abortion drug, is deadly to unborn babies and dangerous to women — especially those who take it without medical oversight. Confidence that the Trump administration will do anything to curb the harms wrought by the Biden administration’s radical expansion of mail-order abortion drugs, however, is dwindling.
New polling from Cygnal suggests that 32 percent of Republican voters are unmotivated to show up for the midterms “if Republican leaders weaken or abandon pro-life policies.” Trump, who fears impeachment if the GOP loses control of Congress come November, can’t afford to be shunned by the pro-life base that played a pivotal role in electing and reelecting him. Yet, he has deliberately avoided addressing mifepristone and the Biden-era mail-order scheme that has contributed to the deadly drug’s popularity.
Trump’s silence is unsurprising given his history of blaming pro-life issues for Republicans’ political losses. What is surprising to the pro-life organizations and GOP legislators is that their demands that the U.S. Food and Drug Administration at least restore the mifepristone safeguards present during the first Trump administration have yet to manifest in any measurable action.
Pro-lifers believe this stalling is deliberate. SBA List Pro-Life America and Live Action’s Lila Rose used an anonymously-sourced article claiming the FDA head was “Slow Walking a Long-Awaited Abortion Pill Safety Study” to call for FDA Commissioner Marty Makary’s firing. The FDA called the accusation “baseless.”
Sen. Josh Hawley, R-Mo., told The Federalist in a phone call that he also believes, after conversations with Makary, that the FDA’s “safety study thing is just a dead end.” (Read more from “Despite Promise To Be Pro-Life ‘Ally,’ Trump Admin Won’t Regulate Abortion Drug Endangering Women” HERE)
